6 results about "Low pathogenic" patented technology

The invention provides a method for detecting H3, H9 and H10 subtype avian influenza viruses through multiple real-time RT-PCR (Reverse Transcription-Polymerase Chain Reaction), and belongs to the technical field of molecular medicines. The primer group, the probe group, the kit and the like are provided, so that one-stop synchronous detection and accurate typing of avian influenza virus subtypes H3, H9 and H10 can be realized, and the detection efficiency is remarkably improved. The method has excellent specificity, can effectively avoid misjudgment, has extremely high detection sensitivity, can find virus traces in the early stage of infection, and strives for precious time for epidemic situation early warning. The method is convenient to operate, stable and reliable in result and easy to popularize and use, provides powerful technical support for daily monitoring and epidemiological investigation of the low-pathogenicity avian influenza in livestock and poultry farms, and has important practical application value for guaranteeing safe production of the breeding industry and preventing public health risks.

A method for screening and efficiently cultivating bezoar strains belongs to the field of bezoar strain screening, and comprises the following steps: step 1, inoculating a culture medium with low-pathogenicity Escherichia coli for culturing, comparing and observing, picking out single colonies with good growth vigor for subculture, and preserving the strains after culture; 2, taking the primarily screened preserved strain, reviving in four regions of an LB solid culture medium by marking lines, selecting a single colony, putting the single colony into a first gradient liquid bile culture medium, culturing, measuring OD600, and if OD600gt is detected, determining that the single colony is not detected; and 0.6, the strain can be placed in a liquid bile culture medium of the next gradient, and the strain which can grow in the three gradients can be inoculated into fresh oxgall for culture. The method has the advantages that the escherichia coli strain with high beta-glucuronidase activity for efficiently cultivating calculus bovis can be obtained, in-vitro cultivation verifies that the escherichia coli strain has bile resistance, calculus bovis analogues can be obtained, and the physicochemical properties of the calculus bovis analogues are similar to those of natural calculus bovis.

The invention provides a preparation method and application of low-pathogenicity avian influenza virus positive serum, and belongs to the technical field of veterinary biological products. The low-pathogenicity avian influenza virus positive serum with high HI titer and neutralizing titer can be obtained by adopting a method of respectively immunizing the live virus and the inactivated vaccine once. The preparation method disclosed by the invention is not limited to the low-pathogenicity avian influenza virus of a single subtype. The positive serum prepared by the method has the characteristics of good specificity, strong sensitivity and the like, and can be used for technical detection of indirect immunofluorescence, western blot, immunohistochemistry and the like; and the kit can also be used for exogenous virus detection of poultry virus live vaccines, separation and identification of clinical viruses, identification and inspection of live vector vaccines, clinical monitoring of avian influenza viruses, epidemiological investigation and immune effect evaluation of related vaccines.

Angiotensin-converting enzyme 2(ACE2) has been confirmed as a specific receptor for several β group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.

The invention discloses an AQP4-IgG molecular typing detection method and kit for predicting glucocorticoid treatment prognosis of an NMOSD patient, and belongs to the technical field of autoimmune disease diagnosis. The detection method comprises the following steps: preparing patient serum AQP4-IgG, co-incubating the patient serum AQP4-IgG and primary astroglia cells, detecting C3 gene and protein expression quantity through RT-PCR and Western Blot double levels, and comparing with an rAb-53 monoclonal antibody, and judging that the type is a high pathogenic type when the expression quantity is greater than or equal to 1.5 times. The kit comprises an Asian race high-pathogenicity AQP4-IgG standard substance, an rAb-53 reference substance, a C3 detection reagent and an auxiliary reagent. The typing system with 'C3 inductivity' as the core is established for the first time, 20 clinical samples and 12-month follow-up visit verification show that the prognosis reject ratio of patients with high pathogenicity typing is 75%, the prognosis reject ratio of patients with low pathogenicity typing is only 8.3%, early accurate prediction of treatment prognosis is achieved, the blank that existing detection is only qualitative and has no prognosis guidance value is filled, a tool is provided for accurate diagnosis and treatment of NMOSD, and the application prospect is wide.

Bacteria with tumor-targeting capability express, surface displayed, secreted and / or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.